Neurologic, neurocognitive, and brain growth outcomes in human immunodeficiency virus-infected children receiving different nucleoside antiretroviral regimens. Pediatric AIDS Clinical Trials Group 152 Study Team
To compare the impact of three different nucleoside reverse transcriptase inhibitor regimens, zidovudine (ZDV) monotherapy, didanosine (ddI) monotherapy, and ZDV plus ddI combination therapy, on central nervous system (CNS) outcomes in symptomatic human immunodeficiency virus (HIV)-infected children...
Gespeichert in:
| Veröffentlicht in: | Pediatrics (Evanston) 1999-09, Vol.104 (3), p.e32-e32 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e32 |
|---|---|
| container_issue | 3 |
| container_start_page | e32 |
| container_title | Pediatrics (Evanston) |
| container_volume | 104 |
| creator | Raskino, C Pearson, D A Baker, C J Lifschitz, M H O'Donnell, K Mintz, M Nozyce, M Brouwers, P McKinney, R E Jimenez, E Englund, J A |
| description | To compare the impact of three different nucleoside reverse transcriptase inhibitor regimens, zidovudine (ZDV) monotherapy, didanosine (ddI) monotherapy, and ZDV plus ddI combination therapy, on central nervous system (CNS) outcomes in symptomatic human immunodeficiency virus (HIV)-infected children.
Serial neurologic examinations, neurocognitive tests, and brain growth assessments (head circumference measurements and head computed tomography or magnetic resonance imaging studies) were performed in 831 infants and children who participated in a randomized double-blind clinical trial of nucleoside reverse transcriptase inhibitors. The Pediatric AIDS Clinical Trials Group study 152 conducted between 1991 and 1995 enrolled antiretroviral therapy-naive children. Subjects were stratified by age (3 to |
| doi_str_mv | 10.1542/peds.104.3.e32 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_70001948</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>75159358</sourcerecordid><originalsourceid>FETCH-LOGICAL-p149t-29d3100b0b1f3489874a72ea0a3f9e4706097b50947ac27a62ebe0d50780f2383</originalsourceid><addsrcrecordid>eNpdkUtv1DAQxy0EosvClSOyOHBqgl_ZJMdqC6VSBUhdzivHnuxOldjBj0X7OflCuKJcuMyM_vObh2YIectZzRslPi5gY82ZqmUNUjwjK876rlKibZ6TFWOSV4qx5oK8ivGBMaaaVrwkF6Vg03e8WZHfXyEHP_kDmkvqHmPjDw4TnuCSamfpEDQ6egj-VzpSn5PxM0RapGOetaM4z9l5CyMaBGfO9IQhxwrdCCaBpeaIkw3gaAADeEJ3oBbHEYqUqMtmAh_RQhmVMEAKvtTrqdAHnMHFmn4HizoFNPTq9vqebid0aAqxC6inSG-CzwvljaD3Kdsz3YGeX5MXY8nBmye_Jj8-f9ptv1R3325ut1d31cJVnyrRW8kZG9jAR6m6vmuVbgVopuXYg2rZhvXt0LBetdqIVm8EDMBsw9qOjUJ2ck0-_O27BP8zQ0z7GaOBadIOfI77thyc9-oRfP8f-OBzcGW3vRCdlLIrZk3ePUF5mMHul4CzDuf9v1_JPyupmnc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>228333883</pqid></control><display><type>article</type><title>Neurologic, neurocognitive, and brain growth outcomes in human immunodeficiency virus-infected children receiving different nucleoside antiretroviral regimens. Pediatric AIDS Clinical Trials Group 152 Study Team</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Raskino, C ; Pearson, D A ; Baker, C J ; Lifschitz, M H ; O'Donnell, K ; Mintz, M ; Nozyce, M ; Brouwers, P ; McKinney, R E ; Jimenez, E ; Englund, J A</creator><creatorcontrib>Raskino, C ; Pearson, D A ; Baker, C J ; Lifschitz, M H ; O'Donnell, K ; Mintz, M ; Nozyce, M ; Brouwers, P ; McKinney, R E ; Jimenez, E ; Englund, J A</creatorcontrib><description>To compare the impact of three different nucleoside reverse transcriptase inhibitor regimens, zidovudine (ZDV) monotherapy, didanosine (ddI) monotherapy, and ZDV plus ddI combination therapy, on central nervous system (CNS) outcomes in symptomatic human immunodeficiency virus (HIV)-infected children.
Serial neurologic examinations, neurocognitive tests, and brain growth assessments (head circumference measurements and head computed tomography or magnetic resonance imaging studies) were performed in 831 infants and children who participated in a randomized double-blind clinical trial of nucleoside reverse transcriptase inhibitors. The Pediatric AIDS Clinical Trials Group study 152 conducted between 1991 and 1995 enrolled antiretroviral therapy-naive children. Subjects were stratified by age (3 to <30 months of age or 30 months to 18 years of age) and randomized in equal proportions to the three treatment groups.
Combination ZDV and ddI therapy was superior to either ZDV or ddI monotherapy for most of the CNS outcomes evaluated. Treatment differences were observed within both age strata. ZDV monotherapy showed a modest statistically significant improvement in cognitive performance compared with ddI monotherapy during the initial 24 weeks, but for subsequent protection against CNS deterioration no clear difference was observed between the two monotherapy arms.
Combination therapy with ZDV and ddI was more effective than either of the two monotherapies against CNS manifestations of human immunodeficiency virus disease. The results of this study did not indicate a long-term beneficial effect for ZDV monotherapy compared with ddI monotherapy.</description><identifier>ISSN: 0031-4005</identifier><identifier>EISSN: 1098-4275</identifier><identifier>DOI: 10.1542/peds.104.3.e32</identifier><identifier>PMID: 10469815</identifier><identifier>CODEN: PEDIAU</identifier><language>eng</language><publisher>United States: American Academy of Pediatrics</publisher><subject>Adolescent ; AIDS/HIV ; Analysis of Variance ; Anti-HIV Agents - therapeutic use ; Brain - growth & development ; Central Nervous System Diseases - etiology ; Central Nervous System Diseases - prevention & control ; Child ; Child, Preschool ; Cognition - drug effects ; Didanosine - therapeutic use ; Double-Blind Method ; Drug Therapy, Combination ; Female ; HIV Infections - complications ; HIV Infections - drug therapy ; Humans ; Infant ; Intelligence Tests ; Male ; Motor Skills - drug effects ; Pediatrics ; Reverse Transcriptase Inhibitors - therapeutic use ; Zidovudine - therapeutic use</subject><ispartof>Pediatrics (Evanston), 1999-09, Vol.104 (3), p.e32-e32</ispartof><rights>Copyright National Library of Medicine - MEDLINE Abstracts Sep 1999</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10469815$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Raskino, C</creatorcontrib><creatorcontrib>Pearson, D A</creatorcontrib><creatorcontrib>Baker, C J</creatorcontrib><creatorcontrib>Lifschitz, M H</creatorcontrib><creatorcontrib>O'Donnell, K</creatorcontrib><creatorcontrib>Mintz, M</creatorcontrib><creatorcontrib>Nozyce, M</creatorcontrib><creatorcontrib>Brouwers, P</creatorcontrib><creatorcontrib>McKinney, R E</creatorcontrib><creatorcontrib>Jimenez, E</creatorcontrib><creatorcontrib>Englund, J A</creatorcontrib><title>Neurologic, neurocognitive, and brain growth outcomes in human immunodeficiency virus-infected children receiving different nucleoside antiretroviral regimens. Pediatric AIDS Clinical Trials Group 152 Study Team</title><title>Pediatrics (Evanston)</title><addtitle>Pediatrics</addtitle><description>To compare the impact of three different nucleoside reverse transcriptase inhibitor regimens, zidovudine (ZDV) monotherapy, didanosine (ddI) monotherapy, and ZDV plus ddI combination therapy, on central nervous system (CNS) outcomes in symptomatic human immunodeficiency virus (HIV)-infected children.
Serial neurologic examinations, neurocognitive tests, and brain growth assessments (head circumference measurements and head computed tomography or magnetic resonance imaging studies) were performed in 831 infants and children who participated in a randomized double-blind clinical trial of nucleoside reverse transcriptase inhibitors. The Pediatric AIDS Clinical Trials Group study 152 conducted between 1991 and 1995 enrolled antiretroviral therapy-naive children. Subjects were stratified by age (3 to <30 months of age or 30 months to 18 years of age) and randomized in equal proportions to the three treatment groups.
Combination ZDV and ddI therapy was superior to either ZDV or ddI monotherapy for most of the CNS outcomes evaluated. Treatment differences were observed within both age strata. ZDV monotherapy showed a modest statistically significant improvement in cognitive performance compared with ddI monotherapy during the initial 24 weeks, but for subsequent protection against CNS deterioration no clear difference was observed between the two monotherapy arms.
Combination therapy with ZDV and ddI was more effective than either of the two monotherapies against CNS manifestations of human immunodeficiency virus disease. The results of this study did not indicate a long-term beneficial effect for ZDV monotherapy compared with ddI monotherapy.</description><subject>Adolescent</subject><subject>AIDS/HIV</subject><subject>Analysis of Variance</subject><subject>Anti-HIV Agents - therapeutic use</subject><subject>Brain - growth & development</subject><subject>Central Nervous System Diseases - etiology</subject><subject>Central Nervous System Diseases - prevention & control</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Cognition - drug effects</subject><subject>Didanosine - therapeutic use</subject><subject>Double-Blind Method</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>HIV Infections - complications</subject><subject>HIV Infections - drug therapy</subject><subject>Humans</subject><subject>Infant</subject><subject>Intelligence Tests</subject><subject>Male</subject><subject>Motor Skills - drug effects</subject><subject>Pediatrics</subject><subject>Reverse Transcriptase Inhibitors - therapeutic use</subject><subject>Zidovudine - therapeutic use</subject><issn>0031-4005</issn><issn>1098-4275</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkUtv1DAQxy0EosvClSOyOHBqgl_ZJMdqC6VSBUhdzivHnuxOldjBj0X7OflCuKJcuMyM_vObh2YIectZzRslPi5gY82ZqmUNUjwjK876rlKibZ6TFWOSV4qx5oK8ivGBMaaaVrwkF6Vg03e8WZHfXyEHP_kDmkvqHmPjDw4TnuCSamfpEDQ6egj-VzpSn5PxM0RapGOetaM4z9l5CyMaBGfO9IQhxwrdCCaBpeaIkw3gaAADeEJ3oBbHEYqUqMtmAh_RQhmVMEAKvtTrqdAHnMHFmn4HizoFNPTq9vqebid0aAqxC6inSG-CzwvljaD3Kdsz3YGeX5MXY8nBmye_Jj8-f9ptv1R3325ut1d31cJVnyrRW8kZG9jAR6m6vmuVbgVopuXYg2rZhvXt0LBetdqIVm8EDMBsw9qOjUJ2ck0-_O27BP8zQ0z7GaOBadIOfI77thyc9-oRfP8f-OBzcGW3vRCdlLIrZk3ePUF5mMHul4CzDuf9v1_JPyupmnc</recordid><startdate>199909</startdate><enddate>199909</enddate><creator>Raskino, C</creator><creator>Pearson, D A</creator><creator>Baker, C J</creator><creator>Lifschitz, M H</creator><creator>O'Donnell, K</creator><creator>Mintz, M</creator><creator>Nozyce, M</creator><creator>Brouwers, P</creator><creator>McKinney, R E</creator><creator>Jimenez, E</creator><creator>Englund, J A</creator><general>American Academy of Pediatrics</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7TS</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>U9A</scope><scope>7X8</scope></search><sort><creationdate>199909</creationdate><title>Neurologic, neurocognitive, and brain growth outcomes in human immunodeficiency virus-infected children receiving different nucleoside antiretroviral regimens. Pediatric AIDS Clinical Trials Group 152 Study Team</title><author>Raskino, C ; Pearson, D A ; Baker, C J ; Lifschitz, M H ; O'Donnell, K ; Mintz, M ; Nozyce, M ; Brouwers, P ; McKinney, R E ; Jimenez, E ; Englund, J A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p149t-29d3100b0b1f3489874a72ea0a3f9e4706097b50947ac27a62ebe0d50780f2383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Adolescent</topic><topic>AIDS/HIV</topic><topic>Analysis of Variance</topic><topic>Anti-HIV Agents - therapeutic use</topic><topic>Brain - growth & development</topic><topic>Central Nervous System Diseases - etiology</topic><topic>Central Nervous System Diseases - prevention & control</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Cognition - drug effects</topic><topic>Didanosine - therapeutic use</topic><topic>Double-Blind Method</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>HIV Infections - complications</topic><topic>HIV Infections - drug therapy</topic><topic>Humans</topic><topic>Infant</topic><topic>Intelligence Tests</topic><topic>Male</topic><topic>Motor Skills - drug effects</topic><topic>Pediatrics</topic><topic>Reverse Transcriptase Inhibitors - therapeutic use</topic><topic>Zidovudine - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Raskino, C</creatorcontrib><creatorcontrib>Pearson, D A</creatorcontrib><creatorcontrib>Baker, C J</creatorcontrib><creatorcontrib>Lifschitz, M H</creatorcontrib><creatorcontrib>O'Donnell, K</creatorcontrib><creatorcontrib>Mintz, M</creatorcontrib><creatorcontrib>Nozyce, M</creatorcontrib><creatorcontrib>Brouwers, P</creatorcontrib><creatorcontrib>McKinney, R E</creatorcontrib><creatorcontrib>Jimenez, E</creatorcontrib><creatorcontrib>Englund, J A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Physical Education Index</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatrics (Evanston)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Raskino, C</au><au>Pearson, D A</au><au>Baker, C J</au><au>Lifschitz, M H</au><au>O'Donnell, K</au><au>Mintz, M</au><au>Nozyce, M</au><au>Brouwers, P</au><au>McKinney, R E</au><au>Jimenez, E</au><au>Englund, J A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neurologic, neurocognitive, and brain growth outcomes in human immunodeficiency virus-infected children receiving different nucleoside antiretroviral regimens. Pediatric AIDS Clinical Trials Group 152 Study Team</atitle><jtitle>Pediatrics (Evanston)</jtitle><addtitle>Pediatrics</addtitle><date>1999-09</date><risdate>1999</risdate><volume>104</volume><issue>3</issue><spage>e32</spage><epage>e32</epage><pages>e32-e32</pages><issn>0031-4005</issn><eissn>1098-4275</eissn><coden>PEDIAU</coden><abstract>To compare the impact of three different nucleoside reverse transcriptase inhibitor regimens, zidovudine (ZDV) monotherapy, didanosine (ddI) monotherapy, and ZDV plus ddI combination therapy, on central nervous system (CNS) outcomes in symptomatic human immunodeficiency virus (HIV)-infected children.
Serial neurologic examinations, neurocognitive tests, and brain growth assessments (head circumference measurements and head computed tomography or magnetic resonance imaging studies) were performed in 831 infants and children who participated in a randomized double-blind clinical trial of nucleoside reverse transcriptase inhibitors. The Pediatric AIDS Clinical Trials Group study 152 conducted between 1991 and 1995 enrolled antiretroviral therapy-naive children. Subjects were stratified by age (3 to <30 months of age or 30 months to 18 years of age) and randomized in equal proportions to the three treatment groups.
Combination ZDV and ddI therapy was superior to either ZDV or ddI monotherapy for most of the CNS outcomes evaluated. Treatment differences were observed within both age strata. ZDV monotherapy showed a modest statistically significant improvement in cognitive performance compared with ddI monotherapy during the initial 24 weeks, but for subsequent protection against CNS deterioration no clear difference was observed between the two monotherapy arms.
Combination therapy with ZDV and ddI was more effective than either of the two monotherapies against CNS manifestations of human immunodeficiency virus disease. The results of this study did not indicate a long-term beneficial effect for ZDV monotherapy compared with ddI monotherapy.</abstract><cop>United States</cop><pub>American Academy of Pediatrics</pub><pmid>10469815</pmid><doi>10.1542/peds.104.3.e32</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0031-4005 |
| ispartof | Pediatrics (Evanston), 1999-09, Vol.104 (3), p.e32-e32 |
| issn | 0031-4005 1098-4275 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70001948 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adolescent AIDS/HIV Analysis of Variance Anti-HIV Agents - therapeutic use Brain - growth & development Central Nervous System Diseases - etiology Central Nervous System Diseases - prevention & control Child Child, Preschool Cognition - drug effects Didanosine - therapeutic use Double-Blind Method Drug Therapy, Combination Female HIV Infections - complications HIV Infections - drug therapy Humans Infant Intelligence Tests Male Motor Skills - drug effects Pediatrics Reverse Transcriptase Inhibitors - therapeutic use Zidovudine - therapeutic use |
| title | Neurologic, neurocognitive, and brain growth outcomes in human immunodeficiency virus-infected children receiving different nucleoside antiretroviral regimens. Pediatric AIDS Clinical Trials Group 152 Study Team |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T07%3A22%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neurologic,%20neurocognitive,%20and%20brain%20growth%20outcomes%20in%20human%20immunodeficiency%20virus-infected%20children%20receiving%20different%20nucleoside%20antiretroviral%20regimens.%20Pediatric%20AIDS%20Clinical%20Trials%20Group%20152%20Study%20Team&rft.jtitle=Pediatrics%20(Evanston)&rft.au=Raskino,%20C&rft.date=1999-09&rft.volume=104&rft.issue=3&rft.spage=e32&rft.epage=e32&rft.pages=e32-e32&rft.issn=0031-4005&rft.eissn=1098-4275&rft.coden=PEDIAU&rft_id=info:doi/10.1542/peds.104.3.e32&rft_dat=%3Cproquest_pubme%3E75159358%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=228333883&rft_id=info:pmid/10469815&rfr_iscdi=true |